Phase 2 Cervical Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years old
- People who have been diagnosed with locally advanced cervical cancer that has not yet been treated, confirmed by a laboratory tissue test
- People who are generally active and able to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, scoring 0 or 1)
- People whose blood counts meet certain minimum levels — including red blood cells, white blood cells, and platelets (confirm with trial site for specific values)
- People whose kidney function blood test results are within an acceptable range (confirm with trial site)
- People whose liver function blood test results are within an acceptable range (confirm with trial site)
- People who are expected to live for more than 6 months
- People who the lead doctor determines are suitable for a combined treatment of chemotherapy and radiation therapy
- People who do not have obvious signs of active bleeding
- People who have provided written consent to participate before the study begins
Who may not be able to join:
- People whose cancer has come back after previous treatment, or has spread to other parts of the body
- People who have had another type of cancer in the past 5 years (except for certain easily treated skin cancers)
- People who have an active autoimmune disease that requires ongoing medical treatment, or another condition requiring long-term use of large amounts of hormones or immune-suppressing medications
- People who need to take steroid medications (at or above a certain dose) or other immune-suppressing medications within 14 days before joining or during the study
- People who have received a live vaccine within 30 days before joining, or who plan to receive one during the study
- People who have previously had an organ transplant, or who are living with HIV
- People who have a known allergy to large protein-based medications, monoclonal antibodies, or any ingredient in the study drugs
- People who have active hepatitis B or hepatitis C infections, based on specific virus level readings in the blood (confirm with trial site for exact values)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
progression disease free survival; safety of Albumin-Bound Paclitaxel/cisplatin based concurrent chemoradiotherapy followed by Sintilimab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.